A European pharmacotherapeutic agent Roflumilast exploring integrated preclinical and clinical evidences for SARS CoV-2 mediated inflammation to organ damage

yogendra Singh1, Neeraj Fuloria2, Shivkanya Fuloria2, Vetriselvan Subramaniyan3, Waleed Almalki4, Fahad Al-abbasi5, Imran Kazmi5, Sobhit Rajput6, and Gaurav Gupta7

1Maharishi Arvind College of Pharmacy
2AIMST University
3MAHSA University
4Umm Al-Qura University
5King Abdulaziz University
6Aligarh College of Pharmacy
7Suresh Gyan Vihar University

November 8, 2021

Abstract
COVID-19 has spread globally, affecting almost 160 million individuals. Elderly and pre-existing patients (such as diabetes, heart disease and asthma), seems more susceptible to serious illness with COVID-19. Roflumilast was licensed for usage in the European Union in July 2010 as a phosphodiesterase-4 (PDE4) inhibitor. Roflumilast has been shown to decrease bleomycin-induced lung fibrosis, lung hydroxyproline, right heart thickning in animal prophylactic. The current study reviewed existing data that the PDE-4 inhibitor protects not just renal tissues but also other major organ systems after COVID-19 infection by decreasing immune cell infiltration. These immune-balancing effects of roflumilast were related with a decrease in oxidative and inflammatory burden, caspase-3 suppression, and increased PKA/cAMP levels in renal and other organ tissue.

Introduction:
COVID-19 has spread globally, affecting more than 216,867,420 documented occurrences and 4,507,837 fatalities in individuals. Elderly and pre-existing patients (such as diabetes, heart disease and asthma), seems more susceptible to serious illness with COVID-19. Due to changes in blood glucose and other diabetes-related complications, diabetic individuals who become infected can be hard to treat. A significant comorbidity towards the occurrence of SARS CoV-2-related COVID-19 includes inflammatory cytokine storm, acute kidney injury, myocarditis, thrombosis, ARDS, TIA mediated cerebral complication that ultimately leads to multi-organ failure. A recent case report illustrates an atypical initial presentation and subsequent complications throughout the middle-aged man. The person complained of abdominal discomfort and vomiting then was diagnosed with a severe acute renal damage. During the hospitalization, the study participant sustained a myocardial infarction and respiratory failure. This indicates that this patient most likely developed cardiorenal syndrome as a result of COVID-19-associated acute renal injury. Notably, the main contributor to the above-mentioned consequences of organ damage and death is inflammation.

In an early stage of SARS CoV-2 attack, pro-inflammatory cytokines circulating including IFN-γ, IL-1/2/6/8, and TNF-α, directly exacerbate the damage by attracting various leukocyte populations to the site of injury, resulting in a devastating inflammatory pathway. As a result of that excitation of immune cells including the
natural and acquired host defence systems become overloaded, resulting in the release of more proinflammatory cytokines which are accumulated or cleared from the glomerulus, causing damage to the nephron tubular segments and epithelial cell death mediated metabolic dysregulation.\textsuperscript{2, 3} Furthermore, in laboratory experiments, leukocyte–platelet (PLT) function has been proven to be integral to leukocyte recruitment,\textsuperscript{4} and the progression of the vascular inflammation and thrombosis.\textsuperscript{5} In COVID-19 infection, systemic inflammation is linked with a ‘procoagulant’ condition defined by excessively elevated tissue factor and factor VIIa levels. These findings imply that the prothrombotic activity of circulating leukocytes may contribute to the elevated cardiac, cerebral and renal vascular risk observed in individuals infected with COVID-19.\textsuperscript{6} In the early stage of the SARS CoV-2 assault, hyperinflammatory and activation of the immune system, together with oxidation load lead to various pathological changes in renal tissue, including cell proliferation, podocyte (proteinuria), deposition of ECM (extracellular matrix), pro apoptotic factor activation. While the immunosuppression found in the late phase of COVID-19 disease/drug (steroids) associated impairs the body’s defenses, aggravating organ damage.\textsuperscript{7} In addition, the peripheral blood count in SARS CoV-2 patients for monocytes and neutrophils in this comparable time frame suggests immune system dysregulation at the late COVID 19 stage. In addition, the peripheral blood count in SARS CoV-2 patients for monocytes and neutrophils in this comparable time frame suggests immune system dysregulation at the late COVID 19 stage.\textsuperscript{8} Additionally, we observed an elevated concentration of plasma leucocytes (CD10 and CD16, for instance) and abnormal blood neutrophil motility, both of which indicate an increased risk of mortality.\textsuperscript{8, 9} Roflumilast was licensed for usage in the European Union in July 2010 as a phosphodiesterase-4 (PDE4) inhibitor. Roflumilast has been approved as a ‘constraint’ treatment to bronchodilators by the EMA summary and, under the GOLD guidelines, an effect also exists in patients not ‘controlled on the combination of Fixed Dose LABAs like formoterol and ICS such as beclomethasone dipropionate. Moreover, roflumilast coadministration with budesonide in Asian and Caucasians did not affect the state of steady disposition of either drugs and had no consequences for its safety or tolerability which also denote that it may be consumed without or with meal.\textsuperscript{10} However, roflumilast cessation might be because of the medicine that is relatively costly and, subsequent to complex prescription procedures or unpleasant effects, poor understanding of roflumilast indications between the clinicians.\textsuperscript{11} Recently a study results show that roflumilast protects from cerebral ischemia functional sequelae, which may be connected to its anti-inflammatory characteristics.\textsuperscript{12} Another research also shows in particular that roflumilast inhibitor of PDE-4 prevents LPS from releasing NO, IL-1\beta, TNF-\alpha from the production of the macrophage through suppression of activation of SAPK/JNK, p38 MAPK, NF-kB mechanisms.\textsuperscript{13} Roflumilast has been shown to decrease bleomycin-induced lung fibrosis, lung hydroxyproline, right heart thickening in animal prophylactic and curative trials; it has also been shown to prevent intracinary pulmonary artery muscularization. The inhibitor PDE4 was utilised in the bronchoalveolar lavage fluid to diminish bleomycin-induced transcripts for Tumor necrosis factor - alpha, transforming growth factor-beta, connective tissue growth factor synthesis, endothelin-1, a(I)collagen, and mucin Muc5ac in the lung, as well as to decrease the levels of IL-13, Tumor necrosis factor - alpha, and Transforming growth factor-beta. Moreover, lung fibrosis, a(I)collagen, right heart thickness generated by bleomycin have been reduced with roflumilast, but not dexamethasone group.\textsuperscript{14} Additionally, another study found that roflumilast and roflumilast N-oxide suppressed macrophages’ release like cell attracting molecules and TNF-alpha release in lungs.\textsuperscript{15} Inflammation and immunological response are strongly related to increased PDE-4 synthesis. There are five major PDE-4 isoforms. They are PDE4A, PDE4B, PDE4C, PDE4D, and PDE4E. PDE4B is highly upregulated on neutrophils and monocytes, resulting in the discharge of many inflammation-inducing agents.\textsuperscript{16} In contrast to earlier experimental findings, where LPS injection was shown to stimulate TNF production from circulating leukocytes in PDE4B knockout mice, it appears that this transcript detrimental effect in inflammatory conditions has been completely inhibited.\textsuperscript{17} Additionally, suppression of PDE4B repressed apoptotic cell death and inflammation molecule biosynthesis in renal tubular epithelial cell when treated with cisplatin. Previously, when ovalbumin was given to rats’ bronchiolar lavage fluid, PDE4B/D expression was found to be greater than in that of controls. The higher expression of these isoforms was noted in only the lavage fluid of rats with ovalbumin exposure, however, the overexpression of PDE4B only
helped rescue allergic symptoms in this study. The high-dose Roflumilast significantly reduced PDE-4B/D transcripts, suggesting key involvement of these two isoforms in ARDS linked with COVID-19. These data further indicate that inhibitions of both transcripts are adequate to raise cAMP levels in renal tissue that have a protective impact on the kidney. Pre-treatment dosage of Roflumilast additively decreased renal oxidative stress, inflammatory cytokines, and renal tissue MPO expression. The MPO neutrophil enzyme is strongly pro-oxidizing and pro-inflammatory. Thus, the inhibitory effects of roflumilast on inflammatory and oxidative injury in COVID-19 infection-induced acute renal injury may be due to the fact that neutrophil recruitment and migratory restriction. Additionally, a research indicates that roflumilast may be helpful in atherothrombotic disorders as well as inflammatory vasculitis that is not primarily associated with lung damage. Notably, Roflumilast was found to improve glucose uptake and insulin sensitivity. This was linked with stimulation of PKA/cAMP/CREB axis, that leads to PCG-1-dependent activation of mitochondrial energy production.

Fig. 1 Depicts the Possible Role of Roflumilast in SARS CoV-2 Mediated Inflammation to Organ Damage

The current study reviewed existing data that the PDE-4 inhibitor protects not just renal tissues but also other major organ systems after COVID-19 infection by decreasing immune cell infiltration. These immune-balancing effects of roflumilast were related with a decrease in oxidative and inflammatory burden, caspase-3 suppression, and increased PKA/cAMP levels in renal and other organ tissue. The findings observations provide fresh light on the late phase events associated with COVID-19-related inflammation and the mechanisms behind roflumilast’s organ protective effects.

Acknowledgment: Not Applicable.

Funding: There was no specific funding for this study.

Competing Interests: The authors declare no competing interest.

Availability of data and material: No datasets were generated or analyzed during the current study.

Author Contributions

Y.S., N.K.F. and S.F. proposed a study; V.S. and W.H.A. participated in all important intellectual content section of the study; F.A.A. and I.K. prepared figures; S.S.R. and G.G. proofread the whole manuscript. All authors approved the content of the manuscript.

Ethics Declarations

Ethical Approval: Not Applicable

Consent to Participate: Not Applicable

Consent to Publish: Not Applicable

References:


